BEVERLY, MA--(Marketwire - April 01, 2013) - Cellceutix Corporation (OTCBB: CTIX) (the "Company"), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, announces that the Company's abstract on Kevetrin™, Cellceutix's flagship cancer drug candidate in clinical trials at Dana-Farber Cancer Center and Beth Israel Deaconess, has been accepted for poster presentation at the 2013 American Society of Clinical Oncology ("ASCO") Annual Meeting. The annual ASCO meeting is being held in Chicago, Illinois from May 31 through June 4, 2013.
The Company's abstract titled, "A phase I, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a novel p53 targeted therapy, in patients with advanced solid tumors," was selected for presentation during the "General Poster Session: Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics" portion of the symposium. The authors of the poster presentation include clinical and laboratory physicians and staff involved in the study from Dana Farber, Beth Israel Deaconess, and Massachusetts General Hospital, along with Cellceutix scientists.
Cellceutix was informed that the Scientific Program Committee and ASCO Leadership received more than 5,300 submissions for poster consideration at this year's meeting.
"We are proud to have been selected to present our research on Kevetrin to the scientific community at ASCO, especially considering the large number of applicants this year," commented Dr. Krishna Menon, Chief Scientific Officer of Cellceutix. "We are particularly pleased to have been selected for presenting during the high-profile General Poster Session, which allots us additional time for our abstract and extra time for a question and answer session. We receive many inquiries about Kevetrin and its progression in clinical trials and this year's ASCO meeting provides a fantastic platform for us to share the research with our peers."
As a completely new class of chemistry in medicine, Kevetrin™ has significant potential to be a major breakthrough in the treatment of solid tumors. Mechanism of action studies showed Kevetrin's unique ability to affect both wild and mutant types of p53 (often referred to as the "Guardian Angel Gene" or the "Guardian Angel of the Human Genome") and that Kevetrin strongly induced apoptosis (cell death), characterized by activation of Caspase 3 and cleavage of PARP. Activation of p53 also induced apoptosis by inducing the expression of p53 target gene PUMA. p53 is an important tumor suppressor that acts to restrict proliferation by inducing cell cycle checkpoints, apoptosis, or cellular senescence.
In more than 50 percent of all human carcinomas, p53 is limited in its anti-tumor activities by mutations in the protein itself. Currently, there are greater than 10 million people with tumors that contain inactivated p53, while a similar number have tumors in which the p53 pathway is partially abrogated by inactivation of other signaling components. This has left cancer researchers with the grand challenge of searching for therapies that could restore the protein's protective function, which Kevetrin appears to be doing the majority of the time.
Further information on the clinical trial, titled "A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin (Thioureidobutyronitrile) Administered Intravenously, in Patients With Advanced Solid Tumors," is available at: http://clinicaltrials.gov/ct2/show/NCT01664000?term=cellceutix&rank=1
Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol "CTIX". It is an emerging bio-pharmaceutical company focused on the development of its pipeline of compounds targeting areas of unmet medical need. Our flagship compound, Kevetrin™, is an anti-cancer drug which has demonstrated the ability in pre-clinical studies to regulate the p53 pathway and attack cancers which have proven resistant to today's cancer therapies (drug-resistant cancers). Cellceutix also owns the rights to seven other drug compounds, including KM-133, which is in development for psoriasis, and KM-391 for the treatment of the core symptoms of autism. More information is available on the Cellceutix web site at www.cellceutix.com.
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Factors that may impact Cellceutix's success are more fully disclosed in Cellceutix's most recent public filings with the U.S. Securities and Exchange Commission.